DAG1 (Phospho-Tyr892) Antibody

For Research Use Only. Not for use in diagnostic procedures.

Polyclonal

Rabbit

DAG1 (Phospho-Tyr892) Antibody detects endogenous levels of DAG1 only when phosphorylated at Tyr892

Antibodies were produced by immunizing rabbits with synthetic phosphopeptide and KLH conjugates. Antibodies were purified by affinity-chromatography using epitope-specific phosphopeptide. Non-phospho specific antibodies were removed by chromatogramphy usi

Rabbit IgG in phosphate buffered saline (without Mg2+ and Ca2+), pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol.

1 mg/ml (lot specific)

Store at -20 degree C

Small volumes of anti-DAG1 antibody vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.

Phospho-specific Ab

Western Blot (WB)

Western Blot: 1:1000

Western blot analysis DAG1 (Phospho-Tyr892) using UV treated HeLa whole cell lysates

97,441 Da

dystroglycan 1

dystroglycan

Dystroglycan

Alpha-DG; Beta-DG??[Similar Products]

DAG1_HUMAN

This gene encodes dystroglycan, a central component of dystrophin-glycoprotein complex that links the extracellular matrix and the cytoskeleton in the skeletal muscle. The encoded preproprotein undergoes O- and N-glycosylation, and proteolytic processing to generate alpha and beta subunits. Certain mutations in this gene are known to cause distinct forms of muscular dystrophy. Alternative splicing results in multiple transcript variants, all encoding the same protein. [provided by RefSeq, Nov 2015]

DAG1: a cytoskeletal protein that functions as a laminin receptor. Provides a linkage between the subsarcolemmal cytoskeleton and the extracellular matrix. May be involved in autosomal recessive muscular dystrophies. Its dramatic reduction in Duchenne muscular dystrophy leads to a loss of linkage between the sarcolemma and extracellular matrix, rendering muscle fibers more susceptible to necrosis. Dystroglycan also functions as dual receptor for agrin and laminin-2 in the Schwann cell membrane. Binds to several types of arenaviruses. Is a target for the entry of Mycobacterium leprae into peripheral nerve Schwann cells. The muscle and nonmuscle isoforms of dystroglycan differ by carbohydrate moieties but not protein sequence.

Protein type: Cytoskeletal; Membrane protein, integral; Motility/polarity/chemotaxis

Chromosomal Location of Human Ortholog: 3p21

Cellular Component: basement membrane; cytoplasm; cytosol; dystrophin-associated glycoprotein complex; extracellular region; extracellular space; filopodium; focal adhesion; integral to membrane; lamellipodium; nucleoplasm; plasma membrane

Molecular Function: actin binding; alpha-actinin binding; laminin-1 binding; protein binding; SH2 domain binding; structural constituent of muscle; tubulin binding; vinculin binding

Biological Process: cytoskeletal anchoring; extracellular matrix organization and biogenesis; membrane protein ectodomain proteolysis; negative regulation of cell migration; negative regulation of MAPKKK cascade; negative regulation of protein kinase B signaling cascade; NLS-bearing substrate import into nucleus; protein amino acid O-linked glycosylation; regulation of gastrulation; shape changes of embryonic cells; virus-host interaction

Disease: Muscular Dystrophy-dystroglycanopathy (congenital With Brain And Eye Anomalies), Type A, 9; Muscular Dystrophy-dystroglycanopathy (limb-girdle), Type C, 9

All of MyBioSource's Products are for scientific laboratory research purposes and are not for diagnostic, therapeutics, prophylactic or in vivo use. Through your purchase, you expressly represent and warrant to MyBioSource that you will properly test and use any Products purchased from MyBioSource in accordance with industry standards. MyBioSource and its authorized distributors reserve the right to refuse to process any order where we reasonably believe that the intended use will fall outside of our acceptable guidelines.

While every efforts were made to ensure the accuracy of the information provided in this datasheet, MyBioSource will not be liable for any omissions or errors contained herein. MyBioSource reserves the right to make changes to this datasheet at any time without prior notice.

It is the responsibility of the customer to report product performance issues to MyBioSource within 30 days of receipt of the product. Please visit our Terms & Conditions page for more information.